Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
MaxCyte Announces Appointment of Douglas A. Doerfler to Biotechnology Industry Organization's Board of Directors
May 13, 2007
Gaithersburg, Maryland - MaxCyteInc., a clinical-stage cell therapeutics company with a growing pipeline of proprietary and partnered drug candidates, today announced that Douglas A. Doerfler, the Company's president, chief executive officer and director, has been elected to the Board of Directors of the Biotechnology Industry Organization (BIO) and its Health Section Governing Body. Since 2000, he has been a member of BIO's Emerging Companies Section Governing Body and is Co-Chair of BIO's Capital Formation Committee.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in thirty other countries. Its members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.
"This is an exciting time for the biotechnology industry and for companies developing cell therapy products," said Mr. Doerfler. "I am committed to helping BIO advance its goal of fostering innovation and ensuring that, in an increasingly complex environment, the issues of small biotechnology companies are addressed."
MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.